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Switching to second-line antiretroviral therapy in
resource-limited settings: comparison of programmes
with and without viral load monitoring
The ART-LINC of IeDEA Study Group
M
Background: In high-income countries, viral load is routinely measured to
detect failure of antiretroviral therapy (ART) and guide switching to second-line
ART. Viral load monitoring is not generally available in resource-limited settings.
We examined switching from nonnucleoside reverse transcriptase inhibitor (NNRTI)-
basedﬁrst-lineregimenstoproteaseinhibitor-basedregimensinAfrica,SouthAmerica
and Asia.
Design and methods: Multicohort study of 17 ART programmes. All sites monitored
CD4 cell count and had access to second-line ART and 10 sites monitored viral load.
We compared times to switching, CD4 cell counts at switching and obtained adjusted
hazard ratios for switching (aHRs) with 95% conﬁdence intervals (CIs) from random-
effects Weibull models.
Results: A total of 20113 patients, including 6369 (31.7%) patients from 10 pro-
grammes with access to viral load monitoring, were analysed; 576 patients (2.9%)
switched. Low CD4 cell counts at ART initiation were associated with switching in all
programmes. Median time to switching was 16.3 months [interquartile range (IQR)
10.1–26.6] in programmes with viral load monitoring and 21.8 months (IQR 14.0–
21.8)inprogrammeswithoutviralloadmonitoring(P<0.001).MedianCD4cellcounts
at switching were 161cells/ml (IQR 77–265) in programmes with viral load monitoring
and 102cells/ml (44–181) in programmes without viral load monitoring (P<0.001).
Switching was more common in programmes with viral load monitoring during months
7–18 after starting ART (aHR 1.38; 95% CI 0.97–1.98), similar during months 19–30
(aHR0.97;95%CI0.58–1.60)andlesscommonduringmonths31–42(aHR0.29;95%
CI 0.11–0.79).
Conclusion: In resource-limited settings, switching to second-line regimens tends to
occur earlier and at higher CD4 cell counts in ART programmes with viral load
monitoring compared with programmes without viral load monitoring.
 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
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Introduction
In industrialized countries, the prognosis of HIV
infection has improved considerably since highly active
antiretroviral therapy (ART) was introduced in 1995
[1–3]. In low-income countries with a high burden of
HIVand AIDS, ART has become more widely available
in recent years. The World Health Organization (WHO)
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estimatesthatabout3millionpeoplewerereceivingART
in low-income and middle-income countries at the end
of 2007, a 7.5-fold increase during the past 4 years [4].
With increasing exposure to ART, the risk of resistance
and subsequent treatment failure has become more
important, and switching of patients to alternative,
second-line regimens is increasingly needed.
Although HIV-1 RNA concentration (viral load) is
regularly assessed to diagnose treatment failure in high-
income countries [5], viral load measurements are often
not available, or are only available at high cost, in
resource-constrained settings. Costs of second-line drugs
are also high [6]. The lack of viral load monitoring in
resource-limited settings may lead to late switching of
regimens, increase the risk of viral resistance and
jeopardize long-term prognosis: second-line regimens
are the last treatment option for many patients in these
settings. Conversely, if treatment is switched unnecess-
arily, resources may be wasted and future treatment
options reduced. Switching to second-line regimens is
less common in lower-income settings than in high-
income countries [7,8] but direct comparisons of
switching rates between treatment programmes with
and without access to viral load monitoring in resource-
limited settings are lacking at present.
We studied rates of switching to second-line regimens,
time to switching and determinants of switching in a
collaborativenetworkoftreatmentprogrammesinAfrica,
Asia and Latin America that includes both programmes
that routinely monitor viral load, and programmes
without access to viral load monitoring.
Methods
The Antiretroviral Therapy in Lower Income
Countries collaboration
The Antiretroviral Therapy in Lower Income Countries
(ART-LINC) collaboration of the International epide-
miological Databases to Evaluate AIDS (IeDEA) is a
collaborative network of ART programmes, which has
been described in detail elsewhere [9,10]. Brieﬂy,
programmes from resource-constrained settings that
collect data on patient characteristics and treatment
outcomes were eligible for participation in ART-LINC.
In all sites, institutional review boards approved the
participation in ART-LINC.
Inclusion criteria and deﬁnitions
We included all patients aged 16 years and older with
known date of starting ART, who had not previously
received ART, started ARTwith a nonnucleoside reverse
transcriptase inhibitor (NNRTI)-based regimen and had
at least 6 months of follow-up. A switch to a second-line
regimenwasdeﬁnedasachangefromtheinitialNNRTI-
based regimen to a protease inhibitor-based regimen after
at least 6 months of follow-up, because WHO
recommends switching due to treatment failure not
before completion of at least 6 months of therapy [11]. In
addition, at least one nucleoside reverse transcriptase
inhibitor (NRTI) had to be changed. A patient was
considered lost to follow-up if the time between the last
visit and the closing date of the cohort was longer than
1 year.
Stage of disease was deﬁned as less advanced [US Centers
for Disease Control and Prevention (CDC) stage A/B or
WHO stage I/II) or advanced (CDC stage C or WHO
stage III/IV]. Routine viral load monitoring was deﬁned
as at least one viral load measurement between 3 and 9
months after starting ART in at least 50% of patients
treated at that site. Measurements of CD4 cell counts and
RNAvalues closest to the starting date of ART (within 6
months before up to 1 week after the date of starting
ART) were taken as the baseline levels. For CD4 cell
counts below 25cells/ml and HIV viral loads above
100000copies/ml, the time window was extended to
1 year before starting therapy. At switching, the time
window was 3 months before up to 2 weeks after
switching.
In patients who switched to a second-line regimen, we
determinedwhether immunological or virological failure
had occurred during the 3 months before switching and
examined the reasons for switching recorded in the
database. Following WHO criteria [11], we deﬁned
immunological failure as a decline in the CD4 cell count
to the baseline value or below, a decline of at least 50%
from the highest count on treatment or a persistent CD4
cell count below 100cells/ml after 6 months of
antiretroviral therapy. Virological failure was deﬁned as
a plasma HIV viral load value above 10000copies/ml
[11].
Statistical analysis
Patient characteristics at start of ﬁrst-line and second-line
ARTs were compared between sites with and without
viral load monitoring using x
2 tests and Wilcoxon rank
sum tests. We calculated times to switching and rates of
switching per 100 person-years and ﬁtted random-effects
Weibull models, comparing sites with and without
routine viral load monitoring. We plotted Kaplan–Meier
curvesoftheprobabilityofswitchingtosecond-lineART
therapy and obtained P values from log rank tests
comparing programmes with and without virological
monitoring. We measured time from 6 months after start
of ART (baseline) to the time of switching, the time of
the last follow-up visit, or 3 years after baseline,
whichever came ﬁrst. Hazards were not proportional
over time (P¼0.0012 from test of proportional hazards)
[12] and follow-up was, therefore, split into periods
7–18, 19–30 and 31–42 months after starting ART.
Analyses were adjusted for sex, age, calendar year, CD4
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cell count, clinical stage (advanced or less advanced) at
baseline and the number of available antiretroviral drugs
in the clinic (tertiles;  10, 11–13,  14 drugs). We
examined predictors of switching separately for pro-
grammes with and without access to viral load
monitoring and used tests of interaction to determine
whether programmes differed.
We compared CD4 cell counts at the time of switching in
sites with and without routine viral load monitoring and
used linear regression analysis to examine whether
differences persisted when adjusting for age, sex, clinical
stage and CD4 cell count at baseline. The square root of
CD4 cell counts was used in these analyses. In sensitivity
analyses, we restricted data to sites from sub-Saharan
Africa. Allanalyseswere performed using Stataversion 10
(Stata Corporation, College Station, Texas, USA).
Results are presented as hazard ratios with 95%
conﬁdence intervals (CIs) or medians with interquartile
range (IQR).
Results
Sites and study populations
Seventeen treatment programmes from 14 countrieswere
included (Table 1). All sites carried out routine CD4
monitoring and had access to second-line therapy, and 10
sites routinely monitored viral load. The database
included 34715 adult patients of whom 14602 patients
(42.1%) were excluded for the following reasons: 1403
(4.0%)diedbefore6months,11250(32.4%)hadlessthan
6 months of follow-up and 1949 (5.6%) started with a
NNRTI-based ART. A total of 20113 patients, including
6369 patients (31.7%) from programmes with routine
viral load monitoring, and 16591 (82.5%) patients from
sub-Saharan Africa, were analysed. A viral load value at
6 months after ART initiation was available in 58–99% of
patients at sites with routine viral load testing, and 0–7%
at other sites (Table 1).
Table 2 shows patient characteristics separately for
programmes with and without viral load monitoring.
The characteristics of patients at start of ARTwere similar
with respect to age and sex, but median CD4 cell counts
at the start of ARTwere lower in programmes with viral
load monitoring than in programmes without viral load
monitoring (97 versus 129cells/ml, P<0.001). Both in
sites with and without viral load monitoring, the four
most common initial regimens were lamivudine (3TC)
with stavudine (d4T) or zidovudine (ZDV), combined
with efavirenz (EFV) or nevirapine (NVP) (Table 2).
Rates and time to switching
A total of 576 patients (2.9%) switched to a second-line
regimen. The rate of switching overall was 2.4 per 100
person-years (95% CI 2.2–2.6). It was higher in
programmes with access to viral load monitoring than
in programs without: 3.2 (95% CI 2.8–3.6) compared
with 2.0 (95% CI 1.8–2.3) per 100 person-years
(P<0.001). Figure 1 shows the Kaplan–Meier curves
of the probability of switching to a second-line regimen
separately for programmes with and without viral load
monitoring. Switching occurred earlier in programmes
with access to viral load monitoring. Median time to
switching was 16.3 months (IQR 10.1–26.6 months) in
236patients from programmeswithviral loadmonitoring
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CEPREF Abidjan (Co ˆte d’Ivoire) 1999 1941 (46) 1.6 (1.2–2.2) No 139 (7)
1290 ANRS Dakar (Senegal) 1998 194 (0) 0 (0–3.7) Yes 153 (79)
AMPATH Eldoret (Kenya) 2002 3229 (106) 5.0 (4.1–6.0) No 0
AMU Kampala (Uganda) 2002 84 (3) 2.7 (0.9–8.2) Yes 83 (99)
Lighthouse Lilongwe (Malawi) 2000 4082 (9) 0.2 (0.1–0.3) No 0
Connaught Harare (Zimbabwe) 2002 707 (31) 3.5 (2.5–5.0) No 0
Gugulethu Cape Town (South Africa) 2002 1243 (23) 1.8 (1.2–2.6) Yes 1106 (89)
Khayelitsha Cape Town (South Africa) 2001 1527 (45) 2.4 (1.8–3.2) Yes 1444 (95)
Themba Lethu Johannesburg (South Africa) 1999 1874 (97) 6.5 (5.3–7.9) Yes 1127 (60)
PHRU Soweto (South Africa) 2004 439 (2) 0.8 (0.2-3.3) Yes 387 (88)
Morocco Casablanca (Morocco) 1999 231 (8) 2.5 (1.3–5.0) Yes 136 (59)
MTCT-Plus Several
b 2003 1455 (22) 1.7 (1.1–2.5) No 0
PUMA Buenos Aires (Argentina) 2003 136 (6) 5.2 (2.3–11.5) Yes 102 (75)
SOBRHIV Porto Alegre (Brazil) 1996 349 (7) 0.8 (0.4–1.7) Yes 289 (83)
RIOHIV Rio de Janeiro (Brazil) 1996 292 (45) 5.7 (4.3–7.6) Yes 183 (63)
YRG Care Chennai (India) 1996 2114 (122) 3.2 (2.7–3.8) No 154 (7)
HIV-NAT Bangkok (Thailand) 2003 216 (4) 1.0 (0.4–2.6) No 0
Total 20113 (576) 2.4 (2.2–2.6) 10/17 5303 (26)
See Acknowledgements section for further details on participating sites. CI, conﬁdence interval.
aRoutineviralloadmonitoringwasdeﬁnedasatleastonemeasurementbetween3and9monthsafterstartingantiretroviraltherapy,inatleast50%
of patients.
bNetwork including sites in South Africa, Zambia, Kenya, Rwanda, Uganda, Ivory Coast and Thailand.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
and 21.8 months (IQR 14.0–21.8 months) in 340
patients from programmes without viral load monitoring
(P<0.001). The rate of switching tended to be higher in
siteswith virologic monitoring during months 7–18 after
starting ART, similar to during months 19–30 and lower
than in programmes without viral load monitoring
during months 31–42. The adjusted hazard ratios (aHRs)
for the three periods were 1.38 (0.97–1.98, P¼0.07),
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Table 2. Patients characteristics at baseline and at switching to second-line antiretroviral regimen.














Women (%) 4101 (64.4) 8350 (60.8) <0.001 145 (61.4) 181 (53.2) 0.05
Median age [IQR] (years) 34 [30–41] 35 [30–41] <0.001 35 [31–41] 38 [33–44] <0.001
Clinical stage (%) <0.001
Stage available 5831 (91.6) 11588 (84.3) 0 0
Less advanced 2591 (44.4) 3343 (28.9)
Advanced
a 3240 (55.6) 8245 (71.2)
CD4 cell count (cells/ml) <0.001 <0.001
CD4 cell count available 5462 (85.8) 10315 (75.1) 141 (59.7) 261 (76.8)
Median [IQR] 97 [42–163] 129 [60–195] 161 [77–265] 102 [44–181]
HIV-1 viral load (copies/ml)
Viral load available (%) 3750 (58.9) 271 (2.0) 143 (60.6) 14 (4.1)
<10000 (%) 511 (13.6) 71 (49.6%)
10000–100000 (%) 1455 (38.8) 36 (25.2%)
>100000 (%) 1784 (47.6) 36 (25.2%)
Median log viral load [IQR] 5.0 [4.4–5.4] 4.0 [3.4–5.0]
First-line regimens (%) <0.001
3TC d4T EFV 3495 (54.9) 9717 (70.7)
3TC ZDV EFV 1193 (18.7) 1757 (12.8)
3TC d4T NVP 1050 (16.5) 1254 (9.1)
3TC ZDV NVP 358 (5.6) 955 (7.0)
Other 273 (4.3) 61 (0.4)
Second-line regimens (%) <0.001 <0.001
ZDV ddI LPV 114 (48.3) 58 (17.1)
3TC ddI IDV RTV 0 (0) 60 (17.7)
ABC ddI LPV 3 (1.3) 43 (12.7)
d4T ddI LPV 19 (8.1) 1 (0.3)
3TC ZDV LPV 18 (7.6) 18 (5.3)
3TC ZDV IDV RTV 6 (2.5) 28 (8.2)
Other 76 (32.2) 132 (38.8)
Interquartilerangesareshowninsquarebracketsandpercentagesinbrackets.ABC,abacavir;ddI,didanosine;EFV,efavirenz;d4T,stavudine;IQR,
interquartile range; LPV, lopinavir; NVP, nevirapine; RTV: boost of ritonavir; 3TC, lamivudine; ZDV, zidovudine.
aUS Centers for Disease Control and Prevention (CDC) stage C, or World Health Organization (WHO) stages III or IV.
Fig. 1. Kaplan–Meier curves of the probability of switching to second-line antiretroviral regimens in 10 treatment programmes
with virological monitoring and seven programmes without virological monitoring.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
0.97 (0.58–1.60, P¼0.90) and 0.29 (0.11–0.79,
P¼0.02), respectively. The results were similar when,
in addition, adjusting for the ﬁrst-line regimen (3TC d4T
NVP, 3TC d4T EFV, 3TC ZDV EFV, 3TC ZDV NVP,
others).
Amajorityofpatientswhoswitched(316patients;54.9%)
changed both NRTIs. The NRTI component of the
new regimen consisted of zidovudine/didanosine (190
patients; 33.0%), abacavir/didanosine (65; 11.3%), other
drugs combined with didanosine (102; 17.7%), other
drugs combined with abacavir (12; 2.1%), combinations
with tenofovir (65; 11.3%) or other combinations (142;
24.7%). Common protease inhibitors in the second-line
regimen were lopinavir boosted with ritonavir (340
patients; 59.0%), indinavir boosted with ritonavir (140;
24.3%) and nelﬁnavir (57; 9.9%).
CD4 cell count at the time of switching
The median CD4 cell count at the time of switching was
102cells/ml (IQR 44–181cells/ml) in 261 patients from
sites without viral load monitoring compared with
161cells/ml (77–265cells/ml) in 141 patients from sites
with routine viral load monitoring (P<0.001). The
remaining patients did not have a CD4 cell count at the
time of switching. Differences persisted in the multi-
variable regression analyses (P¼0.001).
Predictors and reasons of switching
The baseline CD4 cell count, but not clinical stage, was
associated with switching both in sites with and without
viral load monitoring: the lower the CD4 cell count, the
higher the probability of switching to a second-line
regimen(Table3).Switchingwasmorefrequentinearlier
calendar periods.
Reasons for switching were available for 241 (42%) of
the 576 patients who switched. Switching was due to
treatment failure (179 patients; 74%), toxicity (25; 10%)
andother reasons(37;15%).Atthetimeofswitching,399
(69.3%) of 576 patients had a CD4 cell count, 153
(26.6%) had a viral load measurement and 118 (20.5%)
patients had both. Of 399 patients with available
measurements, 263 patients (66%) had immunological
failure, virological failure or both.
Resultswere similar when restricting analysesto sitesfrom
sub-Saharan Africa. For example, the median time to
switchingwas15.2months(IQR9.8–24.9months)in170
patients from programmes with viral load monitoring and
18.0 months (IQR 12.3–24.2 months) in 212 patients
from programmes without viral load monitoring
(P¼0.04). The median CD4 cell count at the time of
switching was 113cells/ml (IQR 44–186cells/ml) in 149
patientsfromsiteswithoutviralloadmonitoringcompared
with 168cells/ml (85–236cells/ml) in 97 patients from
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Table 3. Predictors of switching to second-line antiretroviral therapy.
Sites with routine viral load
monitoring (n¼5058)
Sites without routine viral load
monitoring (n¼8699)
Variable Adjusted HR (95% CI) P Adjusted HR (95% CI) PP for interaction
a
Age (years) 0.55 0.25 0.23
16–29 1 1
30–39 0.93 (0.62–1.39) 0.93 (0.62–1.39)
40–49 0.69 (0.41–1.17) 1.33 (0.84–2.12)
 50 0.97 (0.47–1.98) 1.46 (0.73–2.91)
Sex 0.91 0.11 0.34
Male 1 1
Female 0.98 (0.68–1.41) 1.36 (0.94–1.98)
Time period of starting ART 0.001 0.06 0.53
<2002 1 1
2002–2004 0.40 (0.25–0.65) 0.58 (0.32–1.03)
2005–2006 0.55 (0.29–1.06) 0.88 (0.45–1.72)
Baseline CD4 cell count (cells/ml) 0.03 <0.001 0.87
<25 4.81 (0.64–35.94) 6.21 (1.47–26.12)
25–49 3.59 (0.47–27.35) 5.12 (1.19–21.97)
50–99 3.13 (0.42–23.59) 4.01 (0.95–16.82)
100–199 2.35 (0.32–17.54) 2.55 (0.61–10.64)
200–349 2.03 (0.26–15.92) 1.50 (0.34–6.69)
 350 1 1
Clinical stage 1.00 0.91 0.67
Less advanced 1 1
Advanced 1.00 (0.55–1.82) 1.02 (0.67–1.57)
Number of antiretroviral drugs available in programme 0.26 0.58 0.45
 10 1 1
11–13 1.96 (0.36–10.82) 1.90 (0.47–7.73)
 14 3.56 (0.78–16.34) 1.04 (0.22–5.05)
ART, antiretroviral therapy; CI, conﬁdence interval; HR, hazard ratio.
aTest for interaction between sites with and without routine viral load monitoring.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
sites with routine viral load monitoring (P¼0.007).
Again, this difference persisted in multivariable regression
(P¼0.003).
Discussion
Many ART programmes in resource-limited settings do
not have access to viral load testing to monitor treatment
response, identify treatment failure and inform decisions
onwhentoswitchtoasecond-lineregimen,buttheyrely
on clinical examinations and, where available, on CD4
cell counts. In this study of ART programmes from sub-
SaharanAfrica,AsiaandLatinAmerica,allsiteshadaccess
to CD4 cell counts and some had access to viral load
monitoring. We could thus study patterns of switching to
second-line regimens in sites with and without viral load
monitoring. We found that patients tended to switch
earlier and at higher CD4 cell counts in programmes
with, compared to programmes without, access to viral
load monitoring. Low CD4 cell counts at the start of
ART predicted switching both in programmes with and
without viral load monitoring, and fewer patients
switched in more recent calendar periods.
Our study included over 20000 patients who started
ART and almost 600 patients who switched to second-
line ART. The decision to measure, or not to measure,
viral load in an individual patient will often be related to
prognosis and the probability of switching to a second-
line regimen. By comparing sites with and without a
policy of monitoring viral load, rather than comparing
patients with and without available viral load measure-
ments, such confounding by the indication to test was
avoided. The deﬁnition we used for second-line ART is
in accordance with WHO recommendations [11] and
was used in a previous analysis of the Me ´decins Sans
Frontie `res (MSF) programmes in Africa, Asia, Latin
America and eastern Europe [8]. Our study includes
patients who were treated in 17 programmes from 14
countries, and results should therefore be applicable to
many other patients on ART in resource-limited
countries. Of note, results were robust when restricting
analyses to programmes from sub-Saharan Africa.
However, we stress that the sites participating in the
ART-LINC collaboration are not necessarily representa-
tive of all sites providing ART in these countries: they
representasampleofprogrammeswithelectronicmedical
record systems [13] and access to CD4 cell counts and
second-line regimens.
A substantial number of patients did not have a CD4 cell
count recorded at the time of switching, and this could
have introduced bias in the comparison of CD4 cell
counts at switching in sites with and without viral load
monitoring. This is unlikely; however, the baseline CD4
cell counts were similar in patients with missing counts in
sites with and without viral load monitoring (data not
shown). We did not examine clinical failure: not all sites
systematically collect data on opportunistic infections and
diagnostic capabilities and criteria vary between sites.
Also, we had no information on adherence or drug
resistance, and data about reasons for switching were
available for only some patients. In a programme of a
faith-basedorganizationinthreecountriesinsub-Saharan
Africa, immunological failure was the most common
reason for switching, followed by virological failure.
Clinical failures were rare [14].
We only considered switching of regimens, as recom-
mended by WHO in case of treatment failure, and not
substitutions of single drugs or other changes. A recent
study comparing Switzerland with the Khayelitsha and
Gugulethu township programmes in South Africa
showed that changes to ﬁrst-line regimens of any type
occurred twice as often in Switzerland than in South
Africa [7]. The difference was, however, explained by a
higher rate of changes due to toxicity or patient
wishesinSwitzerland,whereaschangesdue totreatment
failure were infrequent in both settings [7]. In the
present study, most of the patients with information on
the reason for switching changed regimens because of
treatment failure, and results were similar when analyses
were adjusted for differences in the ﬁrst-line regimens
used in programmes with and without viral load
monitoring.
Both in programmes with and without access toviral load
monitoring, the rates of switching were substantially
higher than in the MSF programmes [8]: the MSF
programmes do not have access to viral load monitoring
and the rate was 0.5 per 100 person-years. Rates were,
however, lower than in the programme in three African
countries, which includes routine viral load monitoring
in all sites: the rate of switching was 4.9 per 100 person-
years [14]. A multicountry survey by the WHO found
highly variable rates of switching to second-line regimens
[15]. It seems unlikely that this variability is explained by
differences in primary resistance to NRTIs or NNRTIs.
At present, viral resistance is rare in most resource-limited
settings, although important levels of resistance have
been reported from Nigeria and north India [16]. The
availability of viral load monitoring and general
differences in clinical practice are more likely expla-
nations: practice varies across sites participating in the
collaboration, even within the same country. For
example, in township programmes in Cape Town,
therapy is switched after two consecutive viral loads
above 5000copies/ml in Khayelitsha, whereas the
threshold is 1000copies/ml in Gugulethu.
A low CD4 cell count when starting ARTwas the most
important predictor of switching to a second-line
regimen, in line with a previous study [14]. Starting
ART earlier might thus not only reduce the high
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mortality during the initial months of ART [7,10,17] but
also help preserve ﬁrst-line regimens. The rate of
switching was lower in more recent calendar years
compared with the early years of the ART scale-up, again
conﬁrming previous ﬁndings [14]. Of note, this was not
explainedbytheincreasein CD4cellcounts atthestart of
ART, which was observed in more recent years [10]: the
effect was evident in analyses adjusted for baseline CD4
cell count, and might reﬂect a change in practice
associated with the substantial increase in patients starting
ART since the early 2000s.
There is debate on the feasibility and cost-effectiveness
of viral load monitoring in the context of scaling up of
ART in resource-limited settings [18–22]. WHO
stipulates that viral load monitoring is desirable, but
not essential, for a public health approach to ART [23].
According to a recent modelling study, routine viral
load monitoring has only limited beneﬁt on survival
and cost-effectiveness is poor [20]. An analysis of
mortality in the ﬁrst year after starting ART showed
similar survival in sites with and without viral load
monitoring [17], and preliminary results of a random-
ized trial led to similar conclusions [24]. The results
from empirical research are reassuring for sites without
access to routine viral load monitoring, but they are
based on short-term follow-up, and the effect of viral
load monitoring on long-term outcomes is unclear at
present. The higher CD4 cell counts at the time of
switching in sites with, compared with sites without,
access to viral load monitoring indicate that treatment
failure is detected earlier in programmes using viral load
monitoring, and this might translate into better clinical
outcomes in the long-term.
In conclusion, we found that in programmes with access
to viral load monitoring, patients tended to switch earlier
and at higher CD4 cell counts than in sites without viral
load monitoring. Future studies should examine what the
consequences of earlier or later switching are for clinical
outcomes. For example, the effect of switching based on
virological failure in patients monitored virologically,
with switching based on immunological and clinical
criteria, could be compared in a randomized trial.
Alternatively, this comparison could be mimicked in
longitudinal, observational studies using causal modelling
[25,26]. Finally, further research is required to determine
the optimal frequency of determining CD4 cell counts
and of measuring viral load to maximize cost-effective-
nessandoptimize patientoutcomesin different settings in
lower income countries.
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